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arge-scale clinical studies have proven that primary and
econdary prevention are effective methods in reducing
yocardial infarction, stroke, and overall mortality. An
nresolved issue is the optimal levels of lipids and blood
ressure to achieve these goals (1,2). National treatment
uidelines have progressively lowered thresholds for treat-
ent initiation and target levels (3,4). Although the recent
rend has been that “lower is better,” the ideal targets for
ow-density lipoprotein cholesterol (LDL-C) and blood
ressure, and the interaction between these 2 parameters,
ave not been clearly defined.
See page 1110
In this issue of the Journal, Chhatriwalla et al. (5) attempt
o clarify the relationship between levels of LDL-C and
ystolic blood pressure and their effects on coronary plaque
rogression. The study incorporated 3,437 patients with
stablished coronary artery disease who were enrolled in 7
linical trials that were stratified into 4 groups according to
lood pressure and LDL-C levels. Changes in atheroma
urden were monitored by serial intravascular ultrasound
IVUS), which was performed at baseline and at 18 to 24
onths with the use of standard parameters. The subgroup
ith very low LDL-C (70 mg/dl) and normal systolic
lood pressure (SBP) (120 mm Hg) displayed the least
rogression in percent atheroma volume (PAV) and total
theroma volume (TAV) (p  0.001 for trend). This group
lso displayed more frequent plaque regression (p  0.01)
ompared with other subgroups. In patients with SBP120
m Hg, very low LDL-C was still associated with less
rogression of PAV, whereas in the group with LDL-C
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r. Tobis is on the Speakers’ Bureau for Boston Scientific.70 mg/dl, normal SBP was not associated with less
rogression of PAV or TAV. These observations suggest
hat lipid lowering may have a larger impact on plaque
rogression compared with blood pressure lowering, which
s consistent with previous findings (6).
This study complements the recent SANDS (Stop Ath-
rosclerosis in Native Diabetics Study) trial (7), where 499
atients with type 2 diabetes were randomized to aggressive
goal LDL-C 70 mg/dl, SBP 115 mm Hg) versus
tandard (goal LDL-C 100 mg/dl, SBP 130 mm Hg)
edical therapy and were evaluated by common carotid
rtery intimal medial thickness during the course of 36
onths. Mean levels (95% confidence interval) for LDL-C
ere 72 and 104 mg/dl, and SBP levels were 117 and 129
m Hg in aggressive versus standard groups, respectively.
Compared with baseline, mean intimal medial thickness
egressed in the aggressive group and progressed in the
tandard group (–0.012 mm vs. 0.038 mm; p  0.001). It is
ecoming increasingly clear from animal and human data
hat a combination of aggressive lipid-lowering and blood
ressure control may be necessary for maximum attenuation
f plaque progression (8,9), improvement in endothelial
unction (10,11), and reduced plasma level markers of
nflammation of oxidative stress (12).
Chhatriwalla et al. (5) provide an interesting commentary
n the need for more aggressive treatment guidelines for
pre-hypertension,” that is, blood pressure of 120 to 139/80
o 89 mm Hg in patients with established coronary artery
isease. Prehypertension has been associated with increased
vent rates (13) and is under-recognized and undertreated.
he lack of large, randomized trials with hard clinical end
oints have likely contributed to a delayed acceptance of the
eed for pharmacological treatment in these individuals.
PRINT (Systolic Blood Pressure Intervention Trial) is a
andomized multicenter trial that will compare intensive
SBP 120 mm Hg) versus standard (SBP 140 mm Hg)
lood pressure control in patients older than 55 years of age
ith an SBP 130 mm Hg and at least 1 other cardiovas-
ular disease (CVD) risk factor. The study will focus on
igh-risk patients, such as those with clinical cardiovascular
isease (not including stroke), patients with stage 3 kidney
isease, and patients without clinical CVD who have other
VD risk factors such as low high-density lipoprotein
HDL). Primary composite end points will include CVD
ortality, nonfatal myocardial infarction, stroke, and heart
ailure. The results of this highly anticipated trial may have
profound influence on how prehypertension is prioritized.
Chhatriwalla et al. (5) use IVUS measurements of ath-
roma volume as a surrogate end point in place of clinical
vents. As distinguished from angiography, which provides
2-dimensional longitudinal image of the artery lumen,
VUS uses high-frequency soundwaves to reveal the athero-
clerotic plaque deposited within the arterial wall. The use
f IVUS provides low-resolution, cross-sectional images of
oronary arteries and is useful because it produces an image
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rom autopsy specimens.
In the REVERSAL (Reversal of Atherosclerosis With
ggressive Lipid Lowering) (14) and ASTROID (A Study
o Evaluate the Effect of Rosuvastatin on Intravascular
ltrasound-Derived Coronary Atheroma Burden) (15) tri-
ls, authors used IVUS to demonstrate that aggressive lipid
anagement was associated with slower plaque progression
nd even plaque regression in patients with known coronary
rtery disease (CAD). In REVERSAL, 80 mg/day of
torvastatin was compared with 40 mg/day of pravastatin in
54 patients with angiographically established CAD who
nderwent IVUS at baseline and at 18 months. For the
rimary end point of percent change in TAV, a significantly
ower rate of progression from baseline was observed in the
torvastatin group (–0.4%) as compared with the pravasta-
in group (2.7%, p  0.02). The ASTROID trial evaluated
he effect of maximally intensive statin therapy with 40
g/day of rosuvastatin in 349 patients with CAD. The
VUS measurements performed at baseline and at 24
onths demonstrated a reduction of total plaque volume by
.8% (–14.7  25.7 mm3) (p  0.001). The medication
ntervention trials published by this IVUS core laboratory
16–19) are a product of a monumental amount of effort
nd 10 years of development and have contributed impres-
ively to our knowledge and understanding of pharmaco-
ogical therapies for atherosclerosis.
We must exercise caution, however, when interpreting
tudies that use atheroma burden measured by IVUS as a
urrogate end point. The acceptance of this parameter is
argely based on evidence that luminal narrowing (20) or
laque progression (21) on IVUS in the left main artery at
ne specific cross section has been associated with future
oronary events in patients with CAD and in the left
nterior descending artery in patients undergoing heart
ransplant (22). However, the interpretation of trials with
he use of IVUS as a surrogate end point must be placed into
erspective: IVUS, although a robust clinical and research
ool, is subject to certain limitations.
In the aforementioned clinical studies, atheroma volume
s obtained by taking the sum of the differences between
xternal elastic membrane (EEM) cross-sectional area and
he luminal cross-sectional area for all available images.
AV is then obtained by first calculating the mean cross-
ectional atheroma area for each pullback study. This area is
hen indexed by multiplying by the average length of the
ntire population of IVUS exams. To our knowledge, this
ethod of calculating TAV, although logical, has never
een directly correlated with clinical event rates even within
hese clinical trials because they were not powered for
linical events. Additionally, there are several sources of
otential error when acquiring these data from intravascular
ltrasound.
Any obstruction or distortion of the border of the EEM
r lumen can contribute to measurement error and decrease
eproducibility. For example, significant artifacts can bereated by regions of heavy calcification, causing one diffi-
ultly in defining the EEM border. Nonuniform rotational
istortion, a phenomenon created by variations in catheter
otation speeds; transducer ring down, a result of acoustic
scillations resulting in high frequency signals that obscure
ear field imaging; and geometric distortion, which occurs
hen the ultrasound beam interrogates a plane that is not
rthogonal to vessel walls, can obscure an operator’s ability
o define the true luminal and EEM borders.
Additionally, variations in pullback speeds between the
aseline and follow-up measurements can interfere with the
alculation of total atheroma volumes. These limitations can
e corrected mathematically when there is a known length
f artery, for example, if one is evaluating intimal hyperpla-
ia within coronary stents. The pullback length from the
aseline and follow-up IVUS can be indexed to the known
ength of the stent. It is less certain that we can do this
ccurately when calculating atheroma volume from 2 sepa-
ate studies where the average difference in pullback length
ay be 10% between anatomic landmarks. The scientific
ommunity could be reassured of the accuracy of this
ethod by having an independent IVUS Core Lab repeat
he analysis of these data.
Although we may use plaque progression/regression on
VUS to deduce that we are producing positive results for
ur patients, the true determination of the impact of our
herapy depends on clinical and mortality end points, which
an only be obtained from large-scale randomized clinical
rials. It must be recognized that a direct relationship
etween atheroma progression and regression on IVUS and
ard clinical events has never been clearly defined. For
xample, it is possible that a greater clinical effect is
roduced by altering plaque composition from lipid-rich to
ore fibrotic tissue, thus stabilizing the atheroma, indepen-
ent of any change in lumen area or plaque volume.
herefore, until clinical outcomes are shown to correspond
ith predictions based on the IVUS surrogates, conclusions
erived from these trials should be considered inferential, to
e used as guides for future trials focused on clinical
utcome measures.
eprint requests and correspondence: Dr. Jonathan M. Tobis,
CLA Medical Center, Medicine, B-976 Factor Building CHS,
0833 LeConte Avenue, Los Angeles, California 90095-3075.
-mail: jtobis@mednet.ucla.edu.
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